Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.

Clin Cancer Res. 2013 Jul 1;19(13):3533-44. doi: 10.1158/1078-0432.CCR-12-3815. Epub 2013 May 14.

2.

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.

Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB.

Cancer Discov. 2011 Jul;1(2):170-85. doi: 10.1158/2159-8290.CD-11-0039. Epub 2011 Jun 7. Erratum in: Cancer Discov. 2012 Aug;2(8):750-1.

3.

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.

Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW.

Cancer Res. 2011 Jun 15;71(12):4061-7. doi: 10.1158/0008-5472.CAN-11-0549. Epub 2011 Apr 8.

4.

Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.

Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.

APMIS. 2013 Oct;121(10):954-66. doi: 10.1111/apm.12152. Epub 2013 Aug 29.

PMID:
23992303
5.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

6.

A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.

Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW.

Clin Cancer Res. 2011 Mar 15;17(6):1331-40. doi: 10.1158/1078-0432.CCR-10-0540. Epub 2011 Jan 25.

7.
8.

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.

Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.

9.

Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.

Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH.

BMC Cancer. 2016 Jul 26;16:531. doi: 10.1186/s12885-016-2600-y.

10.

[Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].

Yang X, Dong Y, Zhang XM, Liang Y, Zhang Y, Meng YT, Wang Y, Wang W, Nong L, Li T, Liao QP.

Zhonghua Bing Li Xue Za Zhi. 2011 Dec;40(12):799-804. Chinese.

PMID:
22336203
11.

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.

Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.

PLoS One. 2012;7(5):e37431. doi: 10.1371/journal.pone.0037431. Epub 2012 May 25.

12.

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N.

Cancer Res. 2010 Sep 1;70(17):6804-14. doi: 10.1158/0008-5472.CAN-10-0409. Epub 2010 Aug 10.

13.

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.

Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT.

Mod Pathol. 2013 Nov;26(11):1525-35. doi: 10.1038/modpathol.2013.96. Epub 2013 May 24.

14.

[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].

Li ZW, Yang ZL, Feng HL, Bian XC, Liu YY, Liu YQ.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):330-5. doi: 10.3760/cma.j.issn.0529-5807.2013.05.009. Chinese.

PMID:
24004591
15.

PTEN-deficient cancers depend on PIK3CB.

Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62. doi: 10.1073/pnas.0802655105. Epub 2008 Aug 28.

16.

Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.

Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J, Broaddus R, Hancock JF, Schmandt R, Lu KH.

Mol Cancer Ther. 2013 Dec;12(12):2847-56. doi: 10.1158/1535-7163.MCT-13-0439. Epub 2013 Sep 27.

17.

PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.

Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ.

Oncogene. 2016 Jul 7;35(27):3607-12. doi: 10.1038/onc.2015.406. Epub 2015 Oct 26.

18.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.

BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26.

19.

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA.

J Clin Invest. 2011 Nov;121(11):4311-21. doi: 10.1172/JCI57909. Epub 2011 Oct 10.

20.

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.

Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, Friedman LS, Belvin M.

Cancer Res. 2010 Feb 1;70(3):1164-72. doi: 10.1158/0008-5472.CAN-09-2525. Epub 2010 Jan 26.

Supplemental Content

Support Center